• Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells
  • Readout for dose-escalating clinical study for first two dose cohorts
  • All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration
  • Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts
  • HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026